Table 1.
F (df1, df2) | Vaccinated (n = 698) | Hesitants (n = 500) | No plans to get vaccinated (n = 456) | |
---|---|---|---|---|
Knowledge of BioNTech | 30.92*** (1, 1645) |
3.46a (0.86) |
3.07b (0.68) |
2.97a,b (0.86) |
Knowledge of Sinovac | 34.26*** (1, 1645) |
3.40c (0.92) |
2.98d (0.72) |
2.87c,d (0.95) |
Perceived susceptibility to infection | 6.82** (1, 1645) |
2.85e (1.00) |
2.67f (0.74) |
2.64e,f (0.83) |
Risks from coronavirus | 2.25 (1, 1645) |
48.65 (22.95) | 48.51 (19.75) | 50.97 (21.12) |
Risks from vaccination in general | 41.84*** (1, 1645) |
36.22 g (25.98) | 38.38 h (19.73) | 49.56 g,h (22.43) |
Benefits of BioNTech | 92.30*** (1, 1645) |
3.70i,j (0.69) |
3.47j,k (0.53) |
3.11i,k (0.76) |
Benefits of Sinovac | 156.36*** (1, 1645) |
3.25 l,m (0.94) |
2.71 m,n (0.76) |
2.16 l,n (0.86) |
Risks from BioNTech | 6.83** (1, 1645) |
3.23o,p (0.77) |
3.33o (0.57) |
3.37p (0.67) |
Risks from Sinovac | 26.88*** (1, 1645) |
3.12q,r (0.84) |
3.25q,s (0.67) |
3.50r,s (0.91) |
Notes. ** p <.01. *** p <.001. a–s Mean is statistically different from the mean of the relevant comparison group indicated by the same letter at a 0.05 significance level. Standard deviations are reported in brackets. All comparisons controlled for gender, age, education, income, party identification and health status.